Calypte Only Company with Full Menu of Tests.

denn noch warten broker? bis das der tod dich von deinen papieren scheidet?

da gehst du von uns ohne einsicht...traurig, traurig..  

Man sollte das ganze Weitsichtig betrachten..  

mit meiner weitsicht hättest du schon VOR MONATEN erkannt, dass es hier nicht nur richtung 0,05$ geht, sondern sogar unter...

deine weitsichtigkeit grenzt schon an realitätsfremde...bzw. es ist nur noch realitätsfremd...  

 

wer hier wirklich arm ist. und zwar das in doppelter hinsicht. arm vom depotwert und der kohle her und vor allem arm im geiste, da du ja scheinbar seit jahren unfähig bist, einsicht zu zeigen und aus deinen fehlern zu lernen.

aber was soll ich jetzt noch weiter auf dir herumhacken, bestraft bist du durch deine sture, uneinsichtige, blinde haltung eh schon.

mitleid hast du dir jedoch trotzdem in keinster art und weise verdient, wenn ich bedenke, was hier schon alles abgelaufen ist.

da kann man nur sagen: du empfängst deine gerechte strafe. die stunde, die du fürchtest, wird dich als willkommene ereilen und das sogar noch eher als du denkst.  

Time & Sales most recent  next page
Rec. Time Action Price Volume
10:06:30 AM Bid 0.078  5000  
10:01:52 AM Trade 0.076  5000  
9:55:50 AM Ask 0.081  5000  
9:55:46 AM Trade 0.077  15000  
9:41:48 AM Ask 0.077  5000  
9:41:42 AM Trade 0.073  5000  
9:41:36 AM Trade 0.073  105000  
9:40:50 AM Trade 0.076  5000  
9:40:48 AM Trade 0.073  3000  
9:40:26 AM Trade 0.072  5000  
9:40:24 AM Trade 0.072  25000  
9:39:58 AM Ask 0.073  5000  
9:39:46 AM Ask 0.076  5000  
9:38:46 AM Ask 0.077  5000  
9:38:44 AM Ask 0.076  5000  
9:38:22 AM Trade 0.075  5000  
9:38:16 AM Trade 0.075  12500  
9:38:16 AM Trade 0.075  5000  
9:38:14 AM Trade 0.075  5000  
9:37:10 AM Trade 0.077  1500  
9:36:56 AM Ask 0.077  5000  
9:36:46 AM Trade 0.076  20000  
9:36:40 AM Trade 0.08  5000  
9:36:40 AM Bid 0.076  5000  
9:36:36 AM Trade 0.08  5000  
9:36:18 AM Trade 0.08  5000  
9:36:18 AM Bid 0.08  5000  
9:36:06 AM Bid 0.076  5000  
9:35:04 AM Trade 0.08  5000  
9:34:56 AM Trade 0.08  10000  
9:34:54 AM Trade 0.08  5000  
9:33:48 AM Trade 0.08  5000  
9:33:40 AM Bid 0.08  5000  
9:33:38 AM Trade 0.08  5000  
9:33:34 AM Trade 0.083  10000  
9:33:32 AM Trade 0.08  5000  
9:33:22 AM Trade 0.08  5000  
9:33:16 AM Ask 0.081  5000  
9:32:52 AM Ask 0.084  5000  
9:31:26 AM Trade 0.085  10000  
9:31:24 AM Trade 0.083  10000  
9:30:46 AM Trade 0.083  5000  
9:30:26 AM Trade 0.083  25000  
9:30:04 AM Trade 0.083  1000  

das ding geht ab wie schmitz-katze, toll was, broker? muhhahahahahahaaha  

Mein depot-wert ist immernoch mein depot-wert, der auf und abgeht..

da mach dir mal keine gedanken, trotzdem danke das du dir sorgen machst aber brauchst du wirklich nicht ; )  

wer hier wirklich arm ist,dass sollen alle leser hier selbst entscheiden und zwar das in doppelter hinsicht,wie du es so umschrieben hast. arm vom depotwert und der kohle her und vor allem arm im geiste, kann nur jemand sein, der Tag und Nacht seine Zeit hier investiert nun wirklich nicht sein wie du es hier tust.. Ich meine wieso soll hier jemand der selbst nicht investiert ist, so seine Zeit verbringen? da du ja scheinbar seit jahren deine kostbare zeit hierher investierst und über Calypte deine gedanken verschwendest zeigt mir deine unfähigkeit selbst etwas auf die beine zu stellen. an deiner einsicht mangelt es auch, das du uns mit deinen kommentaren überzeugen kannst.Einsicht zu zeigen und aus deinen fehlern zu lernen, wäre nun doch einige nummern zu groß für dich .

Deine bestrafung war an dem Tag, wofür du nichts konntest für deine Geburt..  

Betrachte jeden Tag, als den letzten deines Lebens, die Stunde, die du nicht ersehnst, wird dich als Willkommene Überraschung ereilen...

 

das du uns mit deinen kommentaren nicht überzeugen kannst  soll es heißen  

sofern du uns hier nich belogen hast und wirklich mit 300.000 teilen im schnitt zu 0,30? dabei bist, dann hast dui hier eine ganz menge kohle unwiederbringlich verloren. ich bezweifel bei deiner einsichtsfähigkeit auch, dass du überhaupt noch andere werte außer caly im depot hast.

bei deiner sturheit dürftest du nämlich schon deine andere kohle komplett in den sand gesetzt haben. aber das würdest du niemals eingestehen, das würde zu sehr an deinem "denkmal" kratzen, gelle? ein denkmal hast du dir sicherlich schon hier mit deiner nach außen hin uneinsichtigen haltung gegenüber deinem calyinvestment gezeigt.

das du dich dabei mit deiner haltung bei der faktenlage immer lächerlicher machst, merkst du dabei gar nicht.

wen kann ich außer dir nicht überzeugen? lucky vielleicht noch, aber der hat eh den verstand eines 3-jährigen, kein wunder.

broker, ich komme auf deine beerdigung, die da heißt Reverse Splitt, versprochen. Ich werde Dir dann sogar noch ein paar "warme" abschiedswort sagen, danz sicher...  

ich verlange eine sofortige Sperrung von Joelu allias calyritter_die_.
Ich lasse mich nicht beleidigen!!!!!!!!!!!!!
Siehe das Posting von Joelu Nr: 3384.
Diskriminierungsgesetz lässt grüßen.
Lucky  

des englischen mächtig sind (oder es verstehen wollen, bei den filings haben wird as problem hier bei einige granaten ja öfters):

By: roy_hinkley  
30 Nov 2006, 06:27 PM EST
Msg. 69262 of 69263
(This msg. is a reply to 69261 by roy_hinkley.)
Jump to msg. #  
As usual the day ends with no announcements and stock down 6% to $ .082. Unless we hear tomorrow of funding from reneging investors or the newly "identified" investors we can add these failures to Roger Gale's long list of "dropped balls" here at Calypte.

1. Profitability promised by 4th quarter 2006? NOPE
2. Debt only funding by Marr until Calypte is profitable? NOPE
3. Oral test to SFDA by 12-31-2005. Just barely!!
4. Approval of test in 100 days? NOPE
5. Approval in 120 days? NOPE
6. Review in September 2004 by SFDA? Oops slipped by again
7. Review in October 2006? NOPE or November 2006? NOPE
8. $ 3,000,000 subscriptiuon from "new investors"? Can you say renege.
9. AMEX listing . Uh lost that one too, sorry.
10. A new qualified CEO in 3-6 months. Oops dropped the ball there too.
11. Commitment to get 2.5 million from reneging subscription investors by 11-30-2006. Today WAS the day.
12. Two search firms have not produced any new investors in 4 months.
13. No new sales in last 3 months.

Above is Gale's "baker's dozen" eggs.

What do you do with a man who has failed that miserably since taking over last October I ask you?

Here is the Calypte answer:

On June 28, 2006, the Company entered into an Employment Agreement (the "Agreement") with Mr. Gale, the terms of which were approved by the Compensation Committee of the Company's Board of Directors on June 21, 2006. The Agreement will commence on August 1, 2006 and will continue for a 24-month period. The Agreement will automatically renew for successive 12-month periods, unless it is terminated at least 60 days prior to the expiration of an employment period, in which case it will terminate upon expiration of the then-current employment period. Pursuant to the Agreement, Mr. Gale will receive an annual base salary of $350,000. Upon commencement of the Agreement, Mr. Gale will be awarded 1,500,000 shares of the Company's common stock. Mr. Gale will also be awarded 1,250,000 restricted stock units or similar incentive award within 60 days of the date of the Agreement, which will vest quarterly on a pro rata basis. Mr. Gale will be entitled to receive an annual performance-based bonus of up to 50% of his annual base salary, payable in cash, equity or a combination of the two. Mr. Gale will also be reimbursed for (i) up to $15,000 of personal travel expenses per year, (ii) reasonable relocation expenses incurred in his relocation from London, England to Portland, Oregon,
(iii) housing expenses up to $3,000 per month, (iv) automobile expenses up to $800 per month, (v) up to $2,500 for legal and tax advise in connection with his employment in the United States, and (vi) repatriation expenses upon termination of the Agreement. All entitlements under the Agreement cease upon termination for "cause" by the Company, termination without cause by Mr. Gale and Mr. Gale's death or disability. Termination for "cause" is defined as personal dishonesty, incompetence, failure to adequately perform duties, willful misconduct, breach of fiduciary duty involving personal profit, willful violation of any law, rule or regulation, conviction of a felony or any material breach of the Agreement. If the Agreement is terminated for any other reason, including, without limitation, termination without cause by the Company and constructive termination, Mr. Gale will be entitled to receive an amount equal to his base salary for a 12-month period, payable in 12 equal monthly installments.

Man o Man just think what he could have gotten if he had a had any successes at all.


and Calytpte had $ 366,000 in bank on 9-30-2006 . Think about it.
Even worse $ 282,000 of that $ 366,000 in bank was monies prepaid for the Mineseeker and U.A.E. orders.

 

Calypte Announces Donation of its Aware(TM) HIV-1/2 Oral Fluid Rapid Tests
Friday December 1, 8:00 am ET  
Gifts to Kenya and UAE in Honor of World AIDS Day


LAKE OSWEGO, Ore., Dec. 1 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC - News), medical diagnostic tests manufacturer for the detection of antibodies to the human immunodeficiency virus (HIV) for the professional point of care (PRO) and over the counter (OTC) segments of the market announced today that it is donating 10,000 Aware(TM) HIV-1/2 OMT (oral fluid) rapid tests to the Ministry of Health for the Republic of Kenya, and, through its Middle East distributor, Joseph and Gionis, LLC, 5,000 tests to the government of the United Arab Emirates (UAE). These donations are in honor of World AIDS Day.
ADVERTISEMENT


Calypte's Aware(TM) HIV-1/2 oral fluid rapid tests are approved for sale in both the Republic of Kenya and the UAE, which allows for immediate use of these donated tests.

Professor Jeckoniah Ndinya-Achola, Associate Professor and Consultant Clinical Microbiologist at Kenyatta National Hospital, University of Nairobi noted "under my direct supervision, the Laboratories of the Department of Medical Microbiology, University of Nairobi at Kenyatta National Hospital campus have participated in the evaluation of Calypte's rapid testing device for HIV detection using oral fluid specimens. We have found this device very sensitive and accurate in detecting HIV infection. Besides its ability to detect HIV with the same accuracy as blood based tests, other unique features of this test are its being non-invasive and the relative ease of sample collection. The device is ideal for use by individuals who would like utmost confidentiality and those who would like to be spared the discomfort of blood collection."

Dr. Walid Yousef, vice president of Joseph and Gionis stated, "We have 100,000 of Calypte's Aware(TM) HIV-1/2 oral fluid rapid OTC tests in transit to Dubai from Calypte's Thailand manufacturing site. Joseph and Gionis and Bin Salem GTE, our UAE representative, are working with the UAE government in their trial of free voluntary HIV testing for government employees. Joseph and Gionis will donate 5,000 test kits for the initial trial program. This begins the official launch of the HIV test kit with the December, 2006 World AIDS Day."

Mr. Roger I. Gale, Calypte's Chairman and Chief Executive Officer commented, "We are pleased to share our Aware(TM) HIV-1/2 oral fluid rapid tests in honor of World AIDS Day as we now have approvals in several key countries where such a non-invasive test can help. The relationships we are building with these donations are important to our efforts. Professor Ndinya is well respected and widely considered a dean in the HIV field, as one of the first to discover HIV in Africa. We also have the utmost respect for the work that Joseph and Gionis is doing in the Middle East. Their support on World Aids Day reflects on their attitude in dealing with this pandemic. We look forward to sales of our products expanding into many additional countries throughout the world in 2007 as we do our part in the fight against HIV/AIDS."

About Kenya and the Sub-Saharan Africa Region:

According to the December 2005 AIDS Epidemic Update, published jointly by the Joint United Nations Programme on HIV/AIDS ("UNAIDS") and the World Health Organization, Sub-Saharan Africa has just over 10% of the world's population, but is home to more than 60% of all people living with HIV -- some 25.8 million. In 2005, an estimated 3.2 million people in the region became newly infected, while 2.4 million adults and children died of AIDS.

Kenya has a population of approximately 34 million people of whom approximately 1.3 million live with AIDS. An estimated 140,000 adults and children died of AIDS-related illnesses in 2005. Kenya has a 5-year strategic plan targeting this disease and is one of three countries in the region that has seen a decline in its prevalence. Kenya's HIV prevalence rate in adults has fallen to 6.1% in 2004 from a peak of 10% in the mid-1990s. (Kenya HIV and AIDS Data Booklet, 2005)

About the UAE and the Middle East Region:

This region has a population of approximately 500 million people. According to the same December 2005 UNAIDS report, the advance of AIDS in the Middle East and North Africa has continued, with latest estimates showing that 67,000 people became infected with HIV in 2005. Approximately 510,000 people are living with HIV in the region and an estimated 58,000 adults and children died of AIDS-related illnesses in 2005.

About Joseph and Gionis, LLC:

Joseph and Gionis (www.josephandgionis.com) (Newport Beach, CA) is a premier biotechnology consulting and distribution firm which is dedicated to promoting excellence of product service, biotechnology, health and welfare throughout the Middle East. Joseph and Gionis is a subsidiary of the Joseph and Gionis International Law Firm.

About Calypte Biomedical:

Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV- 1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2005 and its subsequent filings with the SEC.


   Company Contact:                       Investor Relations Contact:
    Theodore R Gwin,                       Tim Clemensen,
    Chief Financial Officer                Rubenstein Investor Relations
    (971) 204-0282                         Phone: (212) 843-9337
    email:tgwin@calypte.com                email:tclemensen@rubensteinir.com



 

du eigentlich von dem investment hast, welches du massiv besitzt!!!!!!!!!!!!

jetzt müssen sie ihren suuuper-tollen-produkte schon verschenken, damit sie überhaupt einer nimmt.

der test ist wirklich überzeugend, lucky.

du hast überhaupt keine ahnung, in welches risiko du dich gestürzt hast. ein abschreckendes beisspiel für mögliche newbies, die wie du, dem englischen überhaupt nicht mächtig sind!!!

oh mann oh mann....  

 

es juckt dich immer noch einzusteigen, GALE?

komm kauf dir endlich welche, sie sind soooo billig. vorher hasat du eh keine ruhe. du warst doch immer so überzeug tvon der bude!  

Ich bin wirklich heilfroh aus der Bude in etwa +/- null rausgekommen zu sein. Du hast wohl recht gehabt - die China Zulassung kommt im naechsten Leben. Warum interessiert Dich die Firma eigentlich so?
Gruss Bio  

Calypte, in Washington, DC, Presents the 10,000 Oral Fluid Rapid HIV Test Donation to the Embassy of Kenya

LAKE OSWEGO, Ore., Dec. 6 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC), medical diagnostic tests manufacturer for the detection of antibodies to the human immunodeficiency virus (HIV) for the professional point of care (PRO) and over the counter (OTC) segments of the market, presented in Washington, DC, 10,000 of its Aware(TM) HIV-1/2 OMT (oral fluid) rapid tests to Ms. Lily Sambu, Deputy Chief of Mission to the Embassy of Kenya. The event took place in the U.S. House Cannon office building hosted by U.S. Congresswoman Darlene Hooley (D-OR) who praised Calypte's donation. "For too long we've seen the effects of HIV/AIDS in the world. It is time we find a better way to test individuals without fear of accidental infection," said Representative Hooley. "With Calypte's donation to Kenya, we know there will be more people tested and finding out their status."

Receiving the tests on behalf of His Excellency Peter Ogego, Kenyan Ambassador to the United States, Ms. Sambu said, "This method of testing is wonderful. With these tests one does not need a professional to assist you, which cut down on the stigma of a blood test." Ms. Sambu further added, "We will work with Calypte to further their endeavor with the Ministry of Health."

His Excellency Peter Ogego commented, "While we still await any possible breakthroughs in the search for the HIV/AIDS vaccine, jointly conducted by KAVI (the Kenya's AIDS Virus Initiative) and IAVI (the International AIDS Virus Initiative), the Aware(TM) HIV-1/2 OMT rapid tests are able to help our people to determine their status for subsequent treatment, if they are positive."

"It would therefore be an important facility or tool to identify who needs to be treated -- the sooner the better -- and thereby making an important contribution to the fight against HIV/AIDS," His Excellency Peter Ogego concluded.

Also congratulating Calypte on their donation was U.S. Congressman John Boozman (R-AR) who sits on the House Africa Subcommittee of the International Relations Committee. Representative Boozman is also chairman of the Ivory Coast and West Africa caucuses, and a member of the Kenya Caucus.

"Knowledge is a key component in combating the spread of HIV/AIDS across the world, and especially in Africa," Representative Boozman said. "Any way to make the diagnosis of HIV easier will allow for the proper care and treatment of infected persons, thus resulting in controlling the spread of the virus.

"I applaud Calypte and the efforts of my friend from Oregon to make this humanitarian gesture possible," Representative Boozman added.

Other Members of Congress congratulating Calypte's donation were Congressman Henry Cuellar (D-TX) of Laredo and Congressman Danny Davis (D-IL) of Chicago.

Calypte is headquartered in Congresswoman Hooley's district in Lake Oswego, Oregon, and coordinated the donation with the Congresswoman's office. A champion in the fight against HIV/AIDS, Congresswoman Hooley has continually shown an eagerness to help U. S. companies expand the use of their products into Africa and other affected areas. Calypte's non-invasive rapid HIV tests are approved in Kenya, which will permit their immediate use.

Mr. Roger I. Gale, Calypte's Chairman and Chief Executive Officer commented, "We are pleased to have the support of the Ambassador, our local Congresswoman and other Members of Congress. We believe we are involved in an important humanitarian effort and it is through the support of these important individuals and their organizations that we can best assist in the global fight against AIDS. This donation to the Republic of Kenya, where our products are approved for sale and use, is a way to provide key thought centers with the ability to diagnose HIV/AIDS in situations where such a non-invasive test can be of help. Without the discomfort and risk of a blood test, voluntary testing rates have been shown to increase significantly. One of the fundamental aspects of HIV intervention is identifying infected individuals so that they may be counseled and referred to therapy. We are pleased to lead the way in this effort with our Aware(TM) HIV-1/2 oral fluid rapid test."

About U.S. Congresswoman Darlene Hooley:

Darlene Hooley is the U.S. Representative from Oregon's 5th Congressional District. She has fought hard for and won funding for numerous job creating projects and public investments in the 5th District, including biomedical research funding.

Congresswoman Hooley was elected President of her class of incoming freshman U.S. House members in 1997. During her second term in Congress, she was selected as Whip at Large and served in that role until 2003, when she was named Senior Whip.

About Kenya:

Kenya has a population of approximately 34 million people of whom approximately 1.3 million live with AIDS. An estimated 140,000 adults and children died of AIDS-related illnesses in 2005. Kenya has a 5-year strategic plan targeting this disease and is one of three countries in the region that has seen a decline in its prevalence. Kenya's HIV prevalence rate in adults has fallen to 6.1% in 2004 from a peak of 10% in the mid-1990s. (Kenya HIV and AIDS Data Booklet, 2005)

About Calypte Biomedical:

Calypte Biomedical Corporation (http://www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV- 1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases

 

deines ausstieges noch?

oder bist du womöglich immer noch drin.

mein ziel hier ist es, möglichst viel neue aus der aktie zu halten. werde diesen grenzenlosen betrug noch bis zur durchführung des nächsten RS begleiten. dann sind alle meine prognosen erfüllt und es wird dann wohl auch keine pusher mehr geben.

der nächste RS vernichtet das restkapital der einst großmäuligen pusher hier. dann ist ruhe.

bei dem, was ich hier schon an beleidigungen erfahren habe, sollte es dich nicht wundern, dass ich jetzt diese welle nochmal so richtig reite!  

 

Calypte Announces First Russian Sales Order

LAKE OSWEGO, Ore., Dec. 12 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC), medical diagnostic tests manufacturer for the detection of antibodies to the human immunodeficiency virus (HIV) for the professional point of care (PRO) and over the counter (OTC) segments of the market announced today that it has received the initial order from its distributor in Russia, Ordynka Investments Limited, for 25,000 of its Aware(TM) Oral Fluid (OMT) HIV-1/2 rapid tests for the OTC market in the Russian Federation. This product, designed for use in non-clinical settings, permits significantly greater access to HIV testing. Mr. Vladimir Saveliev, Managing Director of Ordynka Investments Limited, stated "We are happy to be working with Calypte in the hope to be able to help Russia in its fight against the prevention of the spread of the fast growing HIV/AIDS epidemic and this initial order of 25,000 test kits should help the cause. In addition to being safe and painless, oral fluid sampling is very efficient and thereby facilitates high-throughput testing in settings such as the military, prisons, schools and universities. Additionally, oral fluid sampling facilitates testing in many settings, such as outreach or prevalence surveys in remote locations, where drawing blood is difficult or even impossible." Mr. Saveliev continued, "We intend to deliver no less than 500,000 tests to the Russian Federation over the next 12 months and are confident that the need for these products can be greater than this." One of the fundamental aspects of HIV intervention is the identification of infected individuals so that they may be counseled and referred to therapy. Although a portion of HIV infections may be identified through a variety of mandated, institutionalized testing programs, the identification of infections in the general population relies largely on the public's voluntary participation in testing programs. Mr. Roger Gale, Calypte's Chairman and Chief Executive Officer commented, "While HIV testing in Russia is already extensive, our recently approved AwareTM HIV-1/2 OMT (oral fluid) rapid test overcomes several barriers to testing as it is a non-invasive test. As such, we believe it will form the basis for a quality post-testing counseling system - for prevention as well as treatment." Mr. Gale continued, "We have worked closely with Marr Technologies B.V. ("Marr"), our strategic partner and the Company's largest investor, whose principals come from this region, and we are optimistic that their contacts in the region will maximize our ability to serve the needs of the Russian Federation in its plans to contain the HIV/AIDS epidemic." About the Russian Federation: The Russian Federation is home to 143 million people. According to the 2006 Report on the Global AIDS Epidemic jointly published by the Joint United Nations Programme on HIV/AIDS ("UNAIDS") and the World Health Organization ("WHO"), there are 940,000 people living with AIDS in the Russian Federation (as of the end of 2005). According to the WHO, the number of people officially registered with HIV increased almost 100-fold in the past eight years from 3,623 cases in 1997 to about 350,000 cases by the end of 2005. The 2006 Report notes that Russia now has an HIV/AIDS epidemic that is both the biggest in Europe and said to be the fastest growing in the world. The Russian AIDS epidemic has now reached the stage where it is propagating out of high risk groups and into the general population. According to the 2006 report by Transatlantic Partners Against AIDS ("TPAA") titled Key Facts About HIV/AIDS in the Russian Federation, the proportion of Russia's newly reported HIV infections acquired through heterosexual intercourse has grown from 6% in 2001 to close to 27% in 2004. Russia is taking action to reverse this trend and Calypte believes that its non-invasive OTC rapid test can have an immediate positive impact on the effort to increase diagnosis and treatment of HIV/AIDS in this region. About Calypte Biomedical: Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the AwareTM HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

 

http://phx.corporate-ir.net/...ewsArticle&ID=941345&highlight=

 

werden..

Die o.g News ist suuper aber warten wir erst ab was wird wenn China und Indien Zulassungen folgen...  

 

 

12 Mon. ordern nicht schlecht denke ich  

 

Die 500.000 sind ja reine Zukunftsmusik - Fakt sind 25.000. Und wie immer viel Geschwätz aber keinerlei Angaben zum Finanziellen.
Haben sie die vielleicht auch verschenkt, wie die letzten Tests - man weiß es nicht.



Es genügt nicht, keine Gedanken zu haben, man muss auch unfähig sein, sie auszudrücken.